文献速递心脏核医学

定量99mTc-焦磷酸盐心肌摄取:转甲状腺素蛋白稳定治疗后的变化

Quantitative 99mTc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy.
PubMed 文献 · J Nucl Cardiol · 2024-08-10

前瞻性纵向队列研究纳入23例接受转甲状腺素蛋白稳定治疗的ATTR-CA患者(中位2.6年),视觉分级显著下降(P=0.003),SUVmax、CAA和%ID亦显著下降,而超声心动图参数和生物标志物保持稳定。作者认为这些结果可能提示心肌ATTR淀粉样蛋白稳定而非淀粉样负荷消退,需进一步研究。

要点

  • 转甲状腺素蛋白稳定治疗后视觉分级显著下降(P=0.003)。
  • SUVmax、CAA和%ID亦显著下降,血清转甲状腺素蛋白水平改善(P=0.008)。
  • 超声心动图参数、NT-proBNP和eGFR保持稳定,作者认为可能提示淀粉样蛋白稳定而非负荷消退。

核心结论

  • 在接受转甲状腺素蛋白稳定治疗的参与者中观察到99mTc-PYP心肌摄取有利变化,而超声心动图参数和生物标志物保持稳定。
  • 这些结果可能提示心肌ATTR淀粉样蛋白稳定而非淀粉样负荷消退。
  • 需要进一步研究以理解这些发现的含义。

研究设计与样本

  • 前瞻性纵向队列研究,纳入23例接受转甲状腺素蛋白稳定治疗的ATTR-CA参与者,中位随访2.6年。
  • 定量分析包括左心室SUVmax、SUVmean、心脏淀粉样活性(CAA;SUVmean×LV活性体积)和注射剂量百分比(%ID),阈值设为SPECT/CT上左房血池活性浓度的1.5倍以上。
  • 配对连续变量和有序变量的纵向变化采用Wilcoxon符号秩检验分析。

主要发现

  • 治疗后视觉分级显著下降(P=0.003)。
  • SUVmax中位变化-0.75(P=0.011)、CAA中位变化-406.6(P<0.001)、%ID中位变化-0.45(P<0.001)均显著下降。
  • 血清转甲状腺素蛋白水平改善,中位变化+6.5 mg/dL(P=0.008)。
  • 超声心动图参数(整体纵向应变、左心室质量指数和左心室壁厚度)、N末端B型利钠肽原和估算肾小球滤过率保持稳定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究以理解这些发现的含义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Quantitative technetium-99m-pyrophosphate cardiac single-photon emission computed tomography (99mTc-PYP SPECT/CT) is an emerging method for estimating myocardial burden of transthyretin cardiac amyloidosis (ATTR-CA), but its efficacy in monitoring longitudinal changes remains uncertain. We aimed to investigate longitudinal changes in cardiac ATTR amyloid burden following transthyretin stabilization therapy using visual and quantitative 99mTc-PYP SPECT/CT and to relate these with changes in cardiac biomarkers and function. METHODS: This prospective longitudinal cohort study investigated changes in 99mTc-PYP SPECT/CT in 23 participants with ATTR-CA on transthyretin stabilization therapy (median: 2.6 years). Quantitative analysis included left ventricular (LV) standardized uptake values (SUVs) (SUVmax, SUVmean), cardiac amyloid activity (CAA; SUVmean∗LV activity volume), and percent injected dose (%ID) (mean activity concentration∗LV activity volume/injected activity), calculated using a threshold of >1.5 times left atrial blood pool activity concentration on SPECT/CT. Longitudinal changes of paired continuous and ordinal variables were analyzed using Wilcoxon signed-rank test. RESULTS: Following therapy, visual grade decreased significantly (P = 0.003). Several quantitative 99mTc-PYP metrics also decreased significantly: SUVmax (median -0.75, P = 0.011), CAA (median: -406.6, P < 0.001), and %ID (median: -0.45, P < 0.001). Serum transthyretin levels improved (median: +6.5 mg/dL, P = 0.008). Echocardiographic parameters (global longitudinal strain, LV mass index, and LV wall thickness), N-terminal pro-B-type natriuretic peptide, and estimated glomerular filtration rate remained stable. CONCLUSIONS: Favorable changes in 99mTc-PYP myocardial uptake were observed in participants on transthyretin stabilization therapy, whereas echocardiographic parameters and biomarkers remained stable. These results likely signify myocardial ATTR amyloid stabilization rather than amyloid burden regression. Further investigation is needed to understand the implications of these findings.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Vijayakumar S, Pabon AR, Clerc OF, et al. Quantitative 99mTc-pyrophosphate myocardial uptake: Changes on transthyretin stabilization therapy. J Nucl Cardiol. 2024. PMID: 39128784. doi:10.1016/j.nuclcard.2024.102019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。